The Sclavo Vaccine Association (SVA) is a non-profit organization, involving 12 institutions from 6 countries, devoted to support vaccine research and development.

Based in Siena (Italy), where one of the first and most important centers in the world for vaccine development was started at the beginning of the 20th century by the visionary hygienist Achille Sclavo, SVA aims at implementing an ambitious program for the development of next generation vaccines.



The overall aim of SVA is to advance the development of preventive and therapeutic vaccines for both high and low income countries, through the identification and application of novel immunization technologies.

## SVA has extensive experience in the Coordination, Management and Dissemination of European Projects.



## **Coordinator of the following EU projects:**



Horizon 2020

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa SC1-BHC-15-2018 - 815439

Duration: 60 months from 1.10.2019



Innovative Medicine Initiative 2 (IMI2) Systems analysis of adult and pediatric responses to the VSV-ZEBOV Ebola vaccine IMI2-IU-2015-116068

Duration: 60 months from 1.04.2016

www.vsv-eboplus.eu



Innovative Medicine Initiative (IMI)

Standardisation and Development of Assays for Assessment of Influenza Vaccine Correlates of Protection

IMI-JU-2013-115672

www.flucop.eu Duration: 60 months from 1.03.2015



Innovative Medicine Initiative 2 (IMI2)

Vaccine Safety and Immunogenicity Signatures of Human Responses to VSV-ZEBOV

IMI2-JU-2014-115842

Duration: 48 months from 1.03.2015

www.vsv-ebovac.eu



7<sup>th</sup> Framework Programme (FP7)

High Impact Project Advanced Immunization Technologies

HEALTH-2011-280873

Duration: 72 months from 1.10.2011

www.aditecproject.eu

### Partner of the following EU projects:



Horizon 2020 Novel vaccine vectors to resist pathogen challenge

H2020-MSCA-ITN-2018

Duration: 48 months from 1.01.2019

www.vacpath.eu



Horizon 2020

European Network of Vaccine Research and Development

H2020-INFRAIA-2016-2017-730964

www.transvac.org Duration: 60 months from 1.05.2017



7th Framework Programme (FP7)

Innovation Partnership for a Roadmap on Vaccines in Europe FP7-2014-602167

www.iprove-eu.eu Duration: 28 months from 1.12.2013



#### **SVA** activities include:

- ❖ **Support vaccine R&D:** by organizing and coordinating national and international scientific research and development projects involving multiple organizations both private and public;
- ❖ Coordination of European Efforts in Vaccine R&D: by bringing together organizations in the vaccine area and accelerating the European Union's efforts to develop safer and more effective innovative immunization technologies;



- Standardization of immunological assays: by coordinating projects aimed at improving and standardizing the existing immunological assays;
- ❖ **Policy making:** SVA is actively involved in policy activities relating to vaccination, by interacting with the social and scientific communities at the national and international levels.

# **SVA Associated Members**



GSK Vaccines Institute for Global Health, Italy



Università di Siena, Italy



Azienda Ospedaliera Universitaria Senese, Italy



Institute for Research in Biomedicine, Switzerland



Statens Serum Institut, Denmark



University of Gothenburg, Sweden



Academisch Ziekenhuis Leiden. The Netherlands



University of Surrey, United Kingdom



Fondazione Humanitas per la Ricerca, Italy



St. George University of London, United Kingdom



Istituto Nazionale di Genetica Molecolare, Italy

University of Geneva, Switzerland

#### Sclavo Vaccines Association

Via Fiorentina, 1; 53100Siena (Italy) info@sclavo.org



www.sclavo.org